Special report: Drug policy

After months of on-and-off negotiations, the pharmaceutical industry and the regulator finally find common ground and agreed on major points of the new drug policy.

The main sticking point was the revision in prices that kept the two sides from reaching an agreement.

Though the industry is mostly satisfied with what has emerged, some still argue that more changes are needed to make the policy fit for the industry to survive and thrive.

This report collects the views of the industry and the government on the policy.



The new drug policy, approved after hectic backdoor lobbying by pharmaceutical companies, has addressed most of the concerns of the industry besides shielding the image of government in the eyes of public.

Read the full story here.



The long-awaited drug policy has finally arrived, providing relief to the pharmaceutical industry. While a few speculate it will bring in new investment, there are others who are adamant on making further changes to regulate the sector.

Read the full story here.



Shedding light on the predicament of the pharmaceutical industry, a leading drug manufacturer, Getz Pharma, has come up with mixed views about the new drug policy.

Read the full story here.